{"page_content": "Categories Accounting Metric Code Information\nAffordability & PricingNumber of settlements of Abbreviated New \nDrug Application (ANDA) litigation that involved \npayments and/or provisions to delay bringing \nan authorized generic product to market for a \ndefined time periodHC-BP-240b.1 None\nPercentage change in: (1) average list price \nand (2) average net price across U.S. product \nportfolio compared to previous yearHC-BP-240b.2 Not reported\nPercentage change in: (1) list price and (2) net \nprice of product with largest increase compared \nto previous yearHC-BP-240b.2 Not reported\nDrug SafetyList of products listed in the Food and Drug \nAdministration\u2019s (FDA) MedWatch Safety Alerts \nfor Human Medical Products databaseHC-BP-250a.1 No products listed on MedWatch\nNumber of fatalities associated with products \nas reported in the FDA Adverse Event Reporting \nSystemHC-BP-250a.2 None\nNumber of recalls issued, total units recalled HC-BP-250a.3 None\nTotal amount of product accepted for takeback, \nreuse, or disposalHC-BP-250a.4 Not reported\nNumber of FDA enforcement actions taken \nin response to violations of current Good \nManufacturing Practices (cGMP), by typeHC-BP-250a.5 None\nCounterfeit  \nDrugsDescription of methods and technologies used \nto maintain traceability of products throughout \nthe supply chain and prevent counterfeitingHC-BP-260a.1 Not reported \nDiscussion of process for alerting customers and \nbusiness partners of potential or known risks \nassociated with counterfeit productsHC-BP-260a.2 Not reported\nNumber of actions that led to raids, seizure, \narrests, and/or filing of criminal charges related \nto counterfeit productsHC-BP-260a.3 None21\nAPELLIS SUSTAINABILITY REPORT 2021", "metadata": {"source": "NASDAQ_APLS_2021.pdf", "page": 22, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}